ALT
Altimmune, Inc. - Common Stock (ALT)
$43
About Altimmune, Inc. - Common Stock (ALT)
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Details
Daily high
$2.56
Daily low
$2.43
Price at open
$2.56
52 Week High
$6.44
52 Week Low
$2.43
Market cap
498.0M
Dividend yield
-
Volume
121,603
Avg. volume
4.2M
P/E ratio
-3.25
Altimmune, Inc. - Common Stock News
Details
Daily high
$2.56
Daily low
$2.43
Price at open
$2.56
52 Week High
$6.44
52 Week Low
$2.43
Market cap
498.0M
Dividend yield
-
Volume
121,603
Avg. volume
4.2M
P/E ratio
-3.25